July 28 (Reuters) - Canada on Tuesday granted conditional approval to Gilead Sciences Inc 's GILD.O antiviral treatment remdesivir to treat patients with severe symptoms of COVID-19, making it the first approved treatment for the fast-spreading illness in the country.
Remdesivir has become the treatment of choice for many countries against severely ill COVID-19 patients after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
The drug, remdesivir, has been granted emergency or conditional authorization in several countries including the United States, Japan, Singapore and Australia.
Under a program, a small number of patients have been or are being treated with remdesivir in Canada until now. With the authorization of remdesivir, the program will no longer be required to access the drug. (https:// FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19